AqueSys, a life sciences firm focusing on developing treatments for glaucoma, has secured $43.6m in its series D round, according to a SEC filing.
Backers in the round include venture firms Accuitive Medical Ventures, Longitude Capital, Rho Ventures, and SV Life Sciences. Private equity firm the Carlyle Group also backed the round.
All the backers in the latest round also participated in a series C held in 2010 worth $35m. In total, AqueSys has received upwards of $78m in venture backing.
The California-based company is commercialising technology from the University of South California Keck School of Medicine. AqueSys’ primary product is an implant which provides a minimally invasive ab interno procedure with the view to significantly lower the eye-pressure associated with glaucoma.
